Despite these limitations, our findings are in line with previous studies [45,46,47], pointing to an underestimated importance of the RAS pathway in pleura malignant mesothelioma, as suggested by a significantly worse prognosis for patients carrying KRAS mutations. This evidence concerns the gene KRAS and medical procedure.